DNM1L and cancer: Inhibition of DRP1 disrupts these signaling interactions, resulting in reduced mitochondrial fission and decreased CSC viability offering a promising approach to impair mitochondrial dynamics and selectively eliminate CSCs, highlighting the potential of DRP1 as a therapeutic target in cancer treatment [50, 93].